This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a cohort study with two historical comparison cohorts, which was performed in a single centre. Children in the intervention group (2-day L-AmB) received physical examinations and baseline routine tests at study entry, every 10 days for the first month after the therapy, and then monthly for 6 months. Body temperatures were measured 6 times/day during hospitalisation. Abdominal ultrasonography was performed at study entry and at 15, 30 and 90 days after therapy. The follow-up period was 6 months for the three groups. No loss to follow-up was reported.
Analysis of effectiveness
The effectiveness analysis was performed on all of the patients included in the final study samples. The main clinical outcomes were initial response, treatment failure, relapse of leishmaniasis, mean duration of fever and overall success. Initial response was defined as the absence of fever, a clinical improvement and a reduction of spleen size. Treatment failure was considered as the persistence of symptoms and the presence of parasites 2 weeks after therapy, and relapse of leishmaniasis as initial response followed by the reappearance of signs and symptoms of infection. In addition, laboratory parameters were compared at baseline, 15, 30 and 90 days. These included haemoglobin level, white blood cell count, platelet count, ratio of albumin to globulin, level of C-reactive protein and erythrocyte sedimentation rate. Finally, the rates of discontinuation of the therapies were compared (toxicity).
At baseline, the three groups were similar in all characteristics apart from spleen size and haemoglobin level. The spleen size of children receiving MA was significantly larger than that in the intervention group, (p=0.03). The haemoglobin level was significantly higher for children receiving 2 doses of L-AmB than for children receiving 5-day therapy, (p=0.01).
Effectiveness results
In the intervention group, 40 of the 41 children had a successful outcome at 6 months and only 1 child had a relapse at week 5.
In the 5-day L-AmB group, 27 participants had a successful outcome at 6 months, 2 had treatment failure and 1 had a relapse.
In the MA group, 47 children had a successful outcome after 6 months, 3 had treatment failure and 2 had a relapse of leishmaniasis.
There was no statistically significant difference in the response rate after 6 months among the three groups, (p=0.17 for intervention versus 5-day L-AmB; p=0.16 for intervention versus MA).
The mean duration of fever was significantly lower for the intervention group (1.9 +/-0.15 days) than for the 5-day LAmB group (2.77 +/-0.25 days), (p<0.01), or MA group (4.77 +/-0.47 days), (p<0.01).
The average temperature at days 1 and 2 was significantly lower for the intervention group in comparison with the other two groups, (p<0.01).
